Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Oncology
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Oncology
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Oncology
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Oncology
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
blood cancer
Biotech
AstraZeneca cuts early-phase prostate cancer pipeline
AstraZeneca has punted a pair of early-phase prostate cancer programs as part of its quarterly pipeline clear out.
Nick Paul Taylor
Oct 30, 2026 5:03am
Fierce Pharma
Novartis refreshes myelofibrosis bid as Geron flops in ph. 3
Oct 29, 2026 8:15am
Merck KGaA buys Silence in $1.3B deal for blood cancer drug
Oct 19, 2026 8:57am
GSK doubles down on Chimagen with $750M multiple myeloma wager
Sep 15, 2026 7:15am
Silence brings the noise to Takeda with phase 2 blood cancer win
Aug 10, 2026 7:31am
Predicta links with Spanish university to offer blood cancer dx
Jun 11, 2026 8:13am